American Society of Breast Disease

10/31/2025

Longitudinal AI lifts breast cancer risk prediction to new heights
A model that reads past mammograms forecasts a decade ahead.

https://www.openevidence.com/feed/46238

OpenEvidence News
|
Published October 30, 2025
Researchers in the Netherlands quietly rewrote the breast cancer screening playbook this week, unveiling a deep learning prediction algorithm that turns a woman’s mammographic history into a ten-year risk forecast with uncommon clarity. The Multi-Time Point Breast Cancer Risk model (MTP-BCR) sifts through as many as five prior scans plus classical risk factors and posts a 10-year patient-level AUC of 0.80 and a concordance index of 0.82—numbers that eclipse many traditional calculators long embedded in American clinics.[1]

04/06/2025

https://news.weill.cornell.edu/news/2025/04/omega-6-fatty-acid-promotes-the-growth-of-an-aggressive-type-of-breast-cancer?utm_source=join1440&utm_medium=email&utm_placement=newsletter&user_id=66c4be495d78644b3a9fc0bb&fbclid=IwZXh0bgNhZW0CMTEAAR55DgzAvFGDTmxtWk-NdMavRao91a4k9btbnwhWPK8ZkaUv5Uws9aVS47kORg_aem_4I2WSRZ2xiVAJ-pzYeJBEw

Linoleic acid, an omega-6 fatty acid found in seed oils such as soybean and safflower oil, and animal products including pork and eggs, specifically enhances the growth of the hard-to-treat “triple negative” breast cancer subtype, according to a preclinical study led by Weill Cornell Medicine in...

06/13/2021

A novel 16-gene panel can both identify patients with a low risk of recurrence if they were to skip postsurgery radiation therapy, and predict which patients would be unlikely to benefit.

06/13/2021

Breast conservation surgery plus radiotherapy (RT) leads to better outcomes than mastectomy with or without RT for patients with early-stage disease.

02/26/2021

Two of four breast cancer procedures that have no meaningful clinical benefit have increased in use, rather than decreased, with use varying widely across different hospitals.

01/31/2021

Two new breast cancer genetic research studies published in the New England Journal of Medicine.

Gene mutations associated with breast cancer even in women who do not have a history of the disease offer a new way of estimating risk and may lead to future changes screening and management.

12/13/2020

“More women with early-stage breast cancer may safely forgo chemotherapy, suggests an interim analysis that had a median follow-up of 5 years of the large-scale phase 3 RxPONDER trial, presented this week at the San Antonio Breast Cancer Symposium (SABCS) 2020.”

After a median follow-up of 5.1 years, among women with lymph node-positive early-stage breast cancer and a recurrence score of 25 or lower who received adjuvant endocrine therapy with or without chemotherapy, postmenopausal patients had no added benefit from chemotherapy.

12/13/2020

Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases
BMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m3873 (Published 28 October 2020)

Objective To assess the risks of breast cancer associated with different types and durations of hormone replacement therapy (HRT). Design Two nested case-control studies. Setting UK general practices contributing to QResearch or Clinical Practice Research Datalink (CPRD), linked to hospital, mortali...

11/16/2020

A large British study takes another look at the question of the link between hormone replacement therapy and breast cancer.

09/13/2020

Mammography Starting at 40 Cuts Risk of Breast Cancer Death

Yearly mammography before age 50 years, commencing at age 40 or 41 years, was associated with a relative reduction in breast cancer mortality, which was attenuated after 10 years, although the absolute reduction remained constant. Reducing the lower age limit for screening from 50 to 40 years could....

07/12/2020

Lifestyle Choices May Reduce Breast Cancer Risk Regardless of Genetics.